| Recruiting | Anti-CD30 biAb-AATC in Patients With Relapsed/Refractory CD30 Positive Hematopoietic Malignancies NCT05544968 | Medical College of Wisconsin | Phase 1 |
| Recruiting | PET-Adapted First-Line Therapy With Nivolumab for Advanced Hodgkin Lymphoma NCT07209059 | National Research Center for Hematology, Russia | Phase 2 |
| Not Yet Recruiting | Atorvaststin and Cardiotoxicity in Acute Myloid Leukemia NCT06684509 | Assiut University | Phase 1 / Phase 2 |
| Active Not Recruiting | A Safety Study of PF-08046044/SGN-35C in Adults With Advanced Cancers NCT06254495 | Seagen, a wholly owned subsidiary of Pfizer | Phase 1 |
| Not Yet Recruiting | Hodgkin's Disease and Chemotherapy Before 40 Years NCT06116929 | Lille Catholic University | N/A |
| Terminated | A Safety Study of PF-08046045/SGN-35T in Adults With Advanced Cancers NCT06120504 | Seagen, a wholly owned subsidiary of Pfizer | Phase 1 |
| Recruiting | Role of Spectral CT in the Evaluation of Cardiotoxicity in Patients With Hodgkin's Lymphoma and Diffuse Large NCT06774326 | IRCCS Azienda Ospedaliero-Universitaria di Bologna | — |
| Completed | Imaging of Chemotherapy-induced Morphological and Functional Lung Changes in Childhood ALL and HD NCT06093334 | University of Erlangen-Nürnberg Medical School | N/A |
| Completed | A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolum NCT05255601 | Bristol-Myers Squibb | Phase 1 / Phase 2 |
| Completed | Fitness Assessment in Young Adults Recovered From Lymphoma NCT05188755 | University Hospital, Clermont-Ferrand | N/A |
| Completed | A Spanish Medical Record Review of Adults With Relapsed or Refractory CD30+ Malignancies When Re-treated With NCT04998331 | Takeda | — |
| Completed | Effects of Prebiotics on Gut Microbiome in Patients Undergoing HSCT NCT04629430 | University of Virginia | N/A |
| Terminated | Cardiac Rehabilitation for Patients Receiving Radiation Therapy for Thoracic Cancers NCT04072393 | Washington University School of Medicine | N/A |
| Active Not Recruiting | A Post-treatment Program to Identify and Manage Complications Related to Oncology or Hematology Treatments in NCT04671693 | Centre Leon Berard | N/A |
| Completed | Assessing Effectiveness and Implementation of an EHR Tool to Assess Heart Health Among Survivors NCT03935282 | Wake Forest University Health Sciences | N/A |
| Active Not Recruiting | Managing Pain and Symptom Burden Caused by Chemotherapy in People With Myeloma or Lymphoma NCT04459416 | Memorial Sloan Kettering Cancer Center | Phase 3 |
| Completed | Study of Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cel NCT03755414 | Washington University School of Medicine | Phase 1 |
| Completed | A Study to Describe Treatment Patterns and Disease Control in Participants With cHL and sALCL in Routine Clini NCT03942263 | Takeda | — |
| Recruiting | A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Tr NCT03739502 | University of Rochester | Phase 2 |
| Completed | Feasibility and Agreement of Remote Evaluation of Resting Heart Rate and Heart Rate Variability in Survivors o NCT03838627 | St. Jude Children's Research Hospital | — |
| Completed | Study to Evaluate the Safety and Efficacy of a Combination of Favezelimab (MK-4280) and Pembrolizumab (MK-3475 NCT03598608 | Merck Sharp & Dohme LLC | Phase 1 / Phase 2 |
| Unknown | OPTmizing Advanced Stage HodgkIn LymphoMa patIentS Therapy NCT03527628 | King Abdullah International Medical Research Center | Phase 2 |
| Active Not Recruiting | A Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Participants With Advan NCT02979522 | Takeda | Phase 1 / Phase 2 |
| Completed | A Study of Nivolumab Plus Brentuximab Vedotin in Patients Between 5 and 30 Years Old, With Hodgkin's Lymphoma NCT02927769 | Bristol-Myers Squibb | Phase 2 |
| Completed | Brentuximab Vedotin in Chinese Participants With Relapsed/Refractory CD30-Positive Hodgkin Lymphoma (HL) or Sy NCT02939014 | Takeda | Phase 2 |
| Terminated | Carfilzomib and TGR-1202 in Treatment of R/R Lymphoma NCT02867618 | Columbia University | Phase 1 / Phase 2 |
| Active Not Recruiting | Administration of T Lymphocytes for Prevention of Relapse of Lymphomas NCT02663297 | UNC Lineberger Comprehensive Cancer Center | Phase 1 |
| Recruiting | Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols NCT02682667 | National Cancer Institute (NCI) | — |
| Completed | Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem Cells and Allogeneic Transplan NCT02639559 | Washington University School of Medicine | Phase 2 |
| Completed | Brentuximab Vedotin in Refractory/Relapsed Hodgkin Lymphoma Treated by ICE NCT02686346 | The Lymphoma Academic Research Organisation | Phase 1 / Phase 2 |
| Terminated | Safety Study of SEA-CD40 in Cancer Patients NCT02376699 | Seagen Inc. | Phase 1 |
| Completed | Phase I Study of Romidepsin, Gemcitabine, Oxaliplatin, and Dexamethasone in Patients With Relapsed/Refractory NCT02181218 | Washington University School of Medicine | Phase 1 |
| Completed | PD and Safety of TG-0054 Combined With G-CSF in Multiple Myeloma, Non-Hodgkin Lymphoma and Hodgkin Disease Pat NCT02104427 | GPCR Therapeutics, Inc. | Phase 2 |
| Active Not Recruiting | Most Closely Matched 3rd Party Rapidly Generated LMP, BARF1 And EBNA1 Specific CTL, EBV-Positive Lymphoma (MAB NCT02287311 | Baylor College of Medicine | Phase 1 |
| Completed | Effect of Product Related Factors on Platelet Concentrate Transfusion Response in Patients With Hematologic Ma NCT02885038 | Etablissement Français du Sang | — |
| Completed | Molecular and Whole-body MR Imaging in Lymphomas NCT02389101 | Turku University Hospital | N/A |
| Completed | Occupational Status and Hematological Disease NCT02057185 | Gruppo Italiano Malattie EMatologiche dell'Adulto | — |
| Completed | Defining PET / CT Protocols With Optimized F18-FDG (Fluorodeoxyglucose) Dose, Focusing on Reduced Radiation Do NCT02378337 | Hospital Sao Rafael | — |
| Completed | Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational) NCT02181738 | Bristol-Myers Squibb | Phase 2 |
| Completed | Study of Melphalan HCl for Injection (Propylene Glycol-free), Carmustine, Etoposide, Cytarabine (BEAM Regimen) NCT01969435 | Washington University School of Medicine | Phase 2 |
| Completed | A Study of Brentuximab Vedotin in Patients With Hodgkin Lymphoma Unsuitable for Chemotherapy Due to Age, Frail NCT02567851 | University of Birmingham | Phase 2 |
| Completed | Cytotoxic T Cells to Treat Relapsed EBV-positive Lymphoma NCT01956084 | Catherine Bollard | Phase 1 |
| Completed | Study of Brentuximab Vedotin Combined With Bendamustine in Patients With Hodgkin Lymphoma NCT01874054 | Seagen Inc. | Phase 1 / Phase 2 |
| Completed | Chemotherapy With or Without Radiation, Low and Intermediate Risk Hodgkins Lymphoma, TXCH-HD-12A NCT01858922 | Baylor College of Medicine | Phase 2 |
| Completed | Bone Marrow and Kidney Transplant for Patients With Chronic Kidney Disease and Blood Disorders NCT01758042 | Massachusetts General Hospital | N/A |
| Completed | A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL NCT01716806 | Seagen Inc. | Phase 2 |
| Recruiting | Tissue Collection for Studies of Lymph Cancer NCT01676805 | National Cancer Institute (NCI) | — |
| Terminated | Immunostimulatory CpG SD-101 + RT in Recurrent/Progressive Lymphoma After Allogeneic Hematopoietic Cell Transp NCT01745354 | Robert Lowsky | Phase 1 |
| Terminated | Phase I/II Study of Abraxane in Recurrent and Refractory Lymphoma NCT01555853 | Washington University School of Medicine | Phase 1 |
| Active Not Recruiting | Administration of TAA-Specific CTLs; Hodgkin or Non-Hodgkin Lymphoma; TACTAL NCT01333046 | Baylor College of Medicine | Phase 1 |
| Terminated | Yttrium-90-labeled Daclizumab With Chemotherapy and Stem Cell Transplant for Hodgkin's Lymphoma NCT01468311 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Terminated | Preservation of Ovarian Function After Hematopoietic Cell Transplant NCT01343368 | Masonic Cancer Center, University of Minnesota | Phase 2 |
| Completed | Lenalidomide Maintenance Therapy Post Autologous Transplant for Hodgkins Lymphoma NCT01207921 | Washington University School of Medicine | Phase 1 |
| Completed | Plerixafor and Sargramostim (GM-CSF) for Mobilization of Allogeneic Sibling Donors NCT01158118 | Washington University School of Medicine | Phase 2 |
| Completed | Infusion of Genetically Modified T Cell for Post Transplant Patients With Relapsed Disease NCT00871702 | Washington University School of Medicine | Phase 1 |
| Completed | Study of Ofatumumab and ESHAP for the Treatment of Hodgkin's Lymphoma NCT01195766 | Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea | Phase 2 |
| Terminated | Personalised Program for Women Treated for Hodgkin Disease NCT01188915 | Institut Paoli-Calmettes | N/A |
| Terminated | Acceleration of Platelet Recovery Following Autologous Peripheral Blood Stem Cell Transplant (PBSC) in Hodgkin NCT01121120 | Tarix Pharmaceuticals | Phase 2 |
| Completed | A Safety and Tolerability Study of PCI-24781 in Subjects With Cancer NCT01149668 | Pharmacyclics LLC. | Phase 1 |
| Completed | Blood Samples to Identify Biomarkers in Haploidentical Graft Recipients NCT01141959 | Fred Hutchinson Cancer Center | — |
| Completed | Safety and PK/PD of TG-0054 in Multiple Myeloma, Non-Hodgkin Lymphoma and Hodgkin Disease Patients NCT01018979 | GPCR Therapeutics, Inc. | Phase 2 |
| Unknown | Brazilian Prospective Hodgkin Lymphoma Registry NCT02589548 | Universidade Federal do Rio de Janeiro | — |
| Terminated | Pilot Study of Unrelated Cord Blood Transplantation NCT00916045 | King's College Hospital NHS Trust | Phase 2 |
| Completed | Azacitidine With Rituximab, Vincristine, and Cyclophosphamide in Refractory Lymphoma NCT00901069 | Shams Shakil | Phase 1 |
| Completed | Intravenous AMD3100 for Collection of Autologous Peripheral Blood Stem Cells in Patients With Lymphoma NCT00733824 | Washington University School of Medicine | Phase 1 / Phase 2 |
| Completed | B-Receptor Signaling in Cardiomyopathy NCT01135849 | Daniel Bernstein | — |
| Terminated | Intentional Rejection of the Donor Graft Using Recipient Leukocyte Infusion(s) Following Nonmyeloablative Allo NCT00909948 | Massachusetts General Hospital | Phase 1 |
| Completed | A Dose-escalation Study of MK-8776 (SCH 900776) With and Without Gemcitabine in Participants With Solid Tumors NCT00779584 | Merck Sharp & Dohme LLC | Phase 1 |
| Completed | Cardiac Effects in Long-Term Survivors of Hodgkin's and Non-Hodgkin's Lymphoma NCT00903890 | University of Rochester | — |
| Completed | Study of the Safety and Tolerability of PCI-24781 in Patients With Lymphoma NCT00724984 | Pharmacyclics LLC. | Phase 1 / Phase 2 |
| Unknown | Functional Assessment of Cancer Therapy - Bone Marrow Transplant NCT01490957 | King Faisal Specialist Hospital & Research Center | — |
| Completed | A Phase II Study of IGEV +/- Bortezomib Before Hign Dose Consolidation in Relapsed/Refractory Hodgkin's Lympho NCT00636311 | Istituto Clinico Humanitas | Phase 2 |
| Completed | Breast Cancer Risk Investigation in Grown-up Hodgkin Lymphoma Patients Treated With MBVD. Multicenter Retrospe NCT07120217 | Federico II University | — |
| Completed | Study of the Safety and Tolerability of Oral Capsule Form of PCI-24781 in Advanced Cancer Patients NCT00562224 | Pharmacyclics LLC. | Phase 1 |
| Completed | Lenalidomide in Relapsed or Refractory Classical Hodgkin Lymphoma NCT00540007 | Washington University School of Medicine | Phase 2 |
| Completed | Use of FDG PET as Predictor of Residual Disease and Subsequent Relapse in Patients With NHL and HD Undergoing NCT00534989 | King Faisal Specialist Hospital & Research Center | N/A |
| Unknown | Prospective Data Collection of Newly Diagnosed Hodgkin's Disease and Non-Hodgkin's Lymphoma Cases NCT00538551 | King Faisal Specialist Hospital & Research Center | — |
| Completed | Phase II Study of Lenalidomide for the Treatment of Relapsed or Refractory Hodgkin's Lymphoma NCT00478959 | University Health Network, Toronto | Phase 2 |
| Completed | Moxifloxacin in the Prevention of Bacteremia After High-dose Chemotherapy and Transplantation of Peripheral St NCT00398411 | University of Cologne | Phase 3 |
| Terminated | Study of Parathyroid Hormone Following Sequential Cord Blood Transplantation From an Unrelated Donor NCT00393380 | The Emmes Company, LLC | Phase 2 |
| Completed | The Effect of Rituximab on Mobilization With AMD3100 (Plerixafor) Plus G-CSF in Patients With Relapsed or Refr NCT00444912 | Genzyme, a Sanofi Company | Phase 2 |
| Terminated | A Study to Evaluate the Ability of Lupron Depot to Enhance Immune Function Following Bone Marrow Transplantati NCT00275262 | Abbott | Phase 2 |
| Completed | Study of TPI 287 in Patients With Advanced Malignancies NCT00113724 | Cortice Biosciences, Inc. | Phase 1 |
| Terminated | Study of Bortezomib (Velcade) in Combination With Dexamethasone to Treat Patients With Relapsed Hodgkin's Lymp NCT00148018 | University of Cologne | Phase 2 |
| Completed | Cytogenetic Analysis of Bone Marrow Specimen Prior to High Dose Chemotherapy and Autologous Stem Cell Transpla NCT00534820 | King Faisal Specialist Hospital & Research Center | N/A |
| Completed | Study Evaluating AMD3100 for Transplantation of Sibling Donor Stem Cells in Patients With Hematological Malign NCT00241358 | Washington University School of Medicine | Phase 1 / Phase 2 |
| Completed | Consent for Obtaining Additional Tissue at the Time of a Diagnostic Biopsy NCT01078350 | Stanford University | — |
| Completed | Prevention of Ovarian Function Damage by a GnRH Analogue During Chemotherapy in Hodgkin Lymphoma Patients NCT01764230 | Masaryk University | N/A |
| Completed | Effect of an Antioxidant on Cancer-Cachectic Patients Undergoing Exercise Training NCT00196885 | German Cancer Research Center | Phase 2 |
| Completed | LMP-specific T-cells for Patients With Relapsed EBV-positive Lymphoma NCT00062868 | Baylor College of Medicine | Phase 1 |
| Completed | Haploidentical Stem Cell Transplant for Treatment Refractory Hematological Malignancies NCT00145613 | St. Jude Children's Research Hospital | Phase 2 |
| Terminated | Pilot Study of Umbilical Cord Blood Transplantation in Adult Patient With Advanced Hematopoietic Malignancies NCT00514722 | University of California, San Francisco | N/A |
| Active Not Recruiting | Clinical, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Hematologi NCT00039676 | National Cancer Institute (NCI) | — |
| Completed | Prophylactic Use of Filgrastim SD/01 in Patients With Hodgkin's Disease Receiving ABVD Chemotherapy NCT00038558 | M.D. Anderson Cancer Center | Phase 3 |
| Terminated | Combination Chemotherapy +/- Radiation in High Risk Hodgkin's Disease NCT00225173 | Stanford University | Phase 2 |
| Completed | Gemcitabine and Hodgkin's Disease Chemotherapy Followed by Peripheral Blood Stem Cell Rescue for Hodgkin's Dis NCT00388349 | Stanford University | Phase 2 |
| Completed | Combination Chemotherapy Plus Low-Dose Radiation Therapy in Treating Patients With Stage I or Stage IIA Hodgki NCT00026208 | Stanford University | Phase 2 |
| Completed | Selective T-Cell Depletion to Reduce GVHD (Patients) Receiving Stem Cell Tx to Treat Leukemia, Lymphoma or MDS NCT00025662 | National Heart, Lung, and Blood Institute (NHLBI) | Phase 2 |
| Completed | A Study to Evaluate the Effect of Weekly PROCRIT (Epoetin Alfa) or Placebo on Anemia and Quality of Life in Ch NCT00261677 | Ortho Biotech Products, L.P. | Phase 3 |
| Completed | Safety and Efficacy of (PN-152,243)/PN-196,444 in the Prevention of Thrombocytopenia NCT00039910 | Pfizer | Phase 3 |
| Unknown | Optimization of the Primary Therapy for Patients With Hodgkin's Disease and Evaluation of PET NCT00188149 | University Hospital Carl Gustav Carus | Phase 4 |
| Completed | High Dose Chemotherapy Followed By PBSC Rescue for HD NCT00186251 | Stanford University | N/A |
| Terminated | Giving Gene Marked EBV Specific T-Cells to Patients Receiving a BMT for Relapsed EBV-Positive Hodgkin Disease NCT00058773 | Baylor College of Medicine | Phase 1 |
| Completed | A Safety/Efficacy Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent CD30+ Hematologic Malign NCT00051597 | Seagen Inc. | Phase 1 / Phase 2 |